Merck-KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

默克(US:MRK) Businesswire·2026-02-27 23:00

公司关键临床数据 - 默克公司的KEYTRUDA联合Padcev方案在肌层浸润性膀胱癌患者中相比新辅助化疗和手术将无事件生存事件风险降低了47% 并将死亡风险降低了35% [1] 公司产品与适应症 - 该联合治疗方案用于可接受顺铂化疗的肌层浸润性膀胱癌患者在手术前后给药 [1]

Merck-KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Reportify